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Post-interventional immunosuppressive treatment and
vascular restenosis in Takayasu’s arteritis
M. C. Park, S. W. Lee, Y. B. Park, S. K. Lee, D. Choi1 and W. H. Shim1
Objective. To investigate the outcome of vascular interventions and the effect of post-interventional immunosuppressive
treatment on the occurrence of vascular restenosis in patients with Takayasu’s arteritis (TA).
Methods. Forty-two patients with TA who had undergone vascular intervention and had serial angiographies before and after
intervention were enrolled. The demographic and clinical data were collected at the time when the interventions were performed,
and the intervention modalities and post-interventional medical treatments were evaluated.
Results. Sixty-three interventions were performed in 42 patients. Twenty (31.7%) interventions restenosed 24.0 21.9 months
after intervention; the likelihood decreasing as time passed. Estimates of arterial patency after intervention were 90.1% at 1 yr,
75.5% at 2 yr, 68.4% at 3 yr, 61.6% at 5 yr and 49.3% at 10 yr. According to the log rank test, interventions that were
performed during the stable stage of the disease (P^ 0.039) and those that were followed by treatment with glucocorticoids and
immunosuppressive agents (P^ 0.044) were independent variables for the maintenance of arterial patency. Their hazard ratios
were 0.30 and 0.41, respectively.
Conclusion. Restenosis occurred in 31.7% of TA patients after intervention. A lower restenosis rate was observed when
the vascular interventions were performed at the stable stage and when post-interventional immunosuppressive treatment was
implemented.
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Takayasu’s arteritis (TA) is a chronic inﬂammatory disease of the
large arteries, primarily affecting the aorta and its main branches
[1–3]. The course of TA usually extends over years with varying
degrees of activity; however, most patients with TA show features
of active disease at the time of diagnosis and present with
symptoms and signs associated with vascular insufﬁciency,
reﬂecting the previous establishment of end-organ ischaemia
[4–10]. Kerr et al. reported that more than 70% of patients with
TA had active disease at the time of diagnosis [11], and in those
with active disease the suppression of active arterial inﬂammation
prior to the development of signiﬁcant vessel damage improved
prognosis [12–16]. In this regard, the role of glucocorticoids in
suppressing systemic symptoms and controlling disease activity
has been emphasized in the literature [5, 12, 13, 17]. Furthermore,
the addition of immunosuppressive agents, such as methotrexate
and azathioprine, to glucocorticoids has been reported as effective
in controlling disease activity and halting angiographic progres-
sion [13–16, 18]. However, the established vascular stenosis is
not usually reversed by medical treatment [11, 19], and surgical or
endovascular interventions have been performed to relieve the
critical vascular stenosis in cases with established lesions with
favourable short-term outcomes [19–24].
Restenosis of vascular lesions that have previously been
revascularized by surgical or endovascular interventions occur
commonly in patients with TA; persistent inﬂammation at the site
of intervention seems to be responsible for this phenomenon
[11, 25–27]. Frequent vascular restenosis can cause cumulative
end-organ damage and can therefore lead to serious complications,
such as valvular heart disease, cerebrovascular accidents,
congestive heart failure and ischaemic heart disease, all of which
are strongly associated with poor prognosis in patients with TA
[6–8]. Thus, maintaining arterial patency after vascular interven-
tions is crucial in preventing further organ damage and improving
the prognosis of patients with TA. In this regard, it is ideal that
vascular interventions are deferred until disease activity is by
medical treatment because aneurysm formation, graft dehiscence
and graft occlusion are more likely to occur during active
inﬂammation. However, most TA patients present with features
of active disease at the time of their diagnosis [11] and, on occasion,
vascular interventions cannot be delayed because critical stenosis
of arteries can lead to poor prognosis. But it is unknown whether
the suppression of persistent vascular inﬂammation at the site of
intervention with glucocorticoids and immunosuppressive agents
can reduce post-interventional vascular restenosis in patients with
TA who present with critical vascular stenosis and impending
organ ischaemia.
We evaluated the outcomes of vascular interventions that had
been performed in patients with TA and identiﬁed the independent
variables associated with the maintenance of the arterial patency
of revascularized lesions. Also, we sought to investigate whether
post-interventional immunosuppressive treatment after surgical or
endovascular interventions reduced vascular restenosis in TA.
Patients and methods
Patients
The medical records of 42 patients (four men and 38 women)
with newly diagnosed TA who were seen at Yonsei University
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Medical Center, Seoul, Korea, between January 1991 and
June 2003 were reviewed retrospectively. All patients fulﬁlled
the American College of Rheumatology classiﬁcation criteria
for TA [28] and had undergone surgical or endovascular interven-
tions after diagnosis. We excluded patients who had been
treated with glucocorticoids or immunosuppressive agents prior
to intervention.
This study was approved by our ethics committee, and all study
participants provided their signed informed consent.
Clinical assessment
At the time of intervention, mean disease durations from symptom
onset and laboratory ﬁndings, including erythrocyte sedimentation
rate (ESR, modiﬁed Westergren method, reference value
<15mm/h in men and <20mm/h in women) and C-reactive
protein (CRP, reference value <0.8mg/dl) were evaluated. Disease
activity was assessed according to the National Institutes of Health
criteria for active disease [11]. These criteria included constitu-
tional symptoms, such as fever and musculoskeletal symptoms,
elevated ESR, features of vascular ischaemia or inﬂammation,
such as claudication, diminished or absent pulse, bruit, vascular
pain, blood pressure difference in the upper or lower extremities,
and typical angiographic ﬁndings. New onset or worsening of two
or more features deﬁned active disease and a decrease in symptoms
and signs or complete resolution of clinical features was indicative
of stable disease.
Vascular interventions and angiographic assessment
The indications for surgical or endovascular interventions
included renovascular hypertension, severe claudication of the
extremities, cerebral infarct, and ischaemic heart disease.
Intervention was considered successful if the residual stenosis
was less than 30% of the luminal diameter with an increase of at
least 50% from the pre-interventional diameter. The interventions
that did not satisfy these criteria were excluded from analysis.
Interventions performed after the age of 45 yr in men and
55 yr in women were also excluded because the risk of athero-
sclerosis increases signiﬁcantly beyond these ages [29], preventing
the clear discrimination of atherosclerotic lesions from vasculitic
stenosis.
Aortic, coronary or peripheral angiographies were performed
on all patients prior to intervention and post-interventional
angiographies were followed to ascertain the patency of the
revascularized lesions. Follow-up angiographies were performed
routinely if the patients did not present new or recurrent symptoms
suggesting restenosis. The schedule for routine follow-up was
at 6–12 months after interventions and then biennially. In those
with features of restenosis, follow-up angiographies were
performed immediately. Mean angiographic follow-up duration
was 33.7 24.4 months (range 6–112 months). Restenosis was
deﬁned as a narrowing of the luminal diameter of more than 70%
from the post-interventional diameter.
Statistical analysis
All statistical analyses were performed using SAS (version 8.1).
Comparisons of disease activity, laboratory data, intervention
modality, and post-interventional medical treatment modality
between interventions that restenosed and those that remained
patent upon follow-up angiography were performed using analysis
of variance (ANOVA) or the independent t-test for continuous
data and the 2 test for categorical data. Survival rates of
arterial patency after intervention were calculated using the
Kaplan–Meier method. A log rank test was performed to identify
independent variables for vascular restenosis, and their hazard
ratios were calculated using a Cox proportional hazards regression
model. P values less than 0.05 were considered statistically
signiﬁcant.
Results
Modalities of interventions and medical treatment
Sixty-three interventions were performed in 42 patients. At the
time of intervention, the mean age of the patients was
32.3 11.3 yr (range 18–54 yr) and mean disease duration was
5.3 4.1 months (range 0–19 months). The surgical intervention
modalities included three endarterectomies (two for subclavian
arteries and one for renal arteries) and 14 bypass grafts (seven
for ascending aortas, four for descending aortas and three for
abdominal aortas). The endovascular intervention modalities
included eight percutaneous transluminal angioplasties (PTA,
four for subclavian arteries, two for coronary arteries, one for
common carotid arteries and one for renal arteries) and 38 PTAs
with stent insertion (13 for subclavian arteries, 10 for common
carotid arteries, nine for renal arteries, ﬁve for coronary arteries
and one for superior mesenteric artery). High-dose glucocorticoids
and immunosuppressive agents were given following 24 of the
interventions. Prednisolone was started at a dose of 1mg/kg/day
for 1 month and tapered to a maintenance dose of 5–10mg/day by
3–4 months. Oral methotrexate was added to glucocorticoids after
21 of the vascular interventions at a starting dose of 7.5mg/week,
and the dose was increased by 2.5mg every 1–2 months to the
maximal dose of 20mg/week. Azathioprine was added to
glucocorticoids after three of the vascular interventions at a
starting dose of 1mg/kg/day to the maximal dose of 2mg/kg/day.
High-dose glucocorticoids were given after 15 interventions
without immunosuppressive agents according to the protocol
described above. The remaining 24 interventions were not followed
with either glucocorticoids or immunosuppressive agents. Aspirin
and ticlodipine were administered after 54 and 47 interventions,
respectively. Table 1 shows the univariate comparisons of
demographic, clinical and laboratory characteristics at the
time of intervention among the interventions followed by
glucocorticoids and immunosuppressive agents, those followed
by glucocorticoids alone, and those that were not followed
by either glucocorticoids or immunosuppressive agent. The
mean age, mean disease duration and laboratory parameters
did not show a signiﬁcant difference among the groups.
However, the interventions that were performed in the active
stage were more likely to be followed by glucocorticoids than
those that were performed in the stable stage (P<0.05). The
addition of immunosuppressive agents was not signiﬁcantly
affected by disease activity.
Outcomes of vascular interventions
Restenosis of previously revascularized lesions occurred after
20 (31.7%) of the 63 interventions after an average of 24.0 21.9
months (range 5–78 months) following intervention. Post-
interventional restenosis were found in nine subclavian arteries,
ﬁve common carotid arteries, two ascending aortas, two renal
arteries, one coronary artery and one descending aorta. Table 2
shows the incidence of vascular restenosis on follow-up angio-
graphy according to the lag time from vascular intervention. Post-
interventional restenosis occurred most frequently within the ﬁrst
year after intervention; the incidence tended to decrease as time
passed.
Table 3 shows the results of the univariate analysis for
comparisons of characteristics at the time of intervention between
the interventions that restenosed and those that remained patent
on follow-up angiography. The mean age, mean disease duration,
laboratory parameters, modality of vascular intervention, and use




















of aspirin or ticlodipine were not different between the two groups,
but disease activity and post-interventional immunosuppressive
treatment showed signiﬁcant differences in vascular outcome.
Seventeen (44.7%) of the 38 interventions performed during the
active stage restenosed, and three (12.0%) of the 25 interventions
performed at the stable stage restenosed. Restenosis occurred
more frequently after interventions performed during the
active stage than after interventions performed at a stable
stage (P<0.05). Two (8.3%) of the 24 interventions that were
followed by glucocorticoid and immunosuppressive agent
treatment restenosed, and six (40.0%) of the 15 interventions
that were followed by glucocorticoids alone restenosed. Twelve
(50.0%) of the 24 interventions that were not followed by
either glucocorticoids or immunosuppressive agents restenosed.
A signiﬁcantly lower restenosis rate was found after interventions
that were followed by glucocorticoids with immunosuppressive
agents compared with those that were followed by glucocorticoids
alone and those that were not followed by medical treatment
(P<0.05). The difference between the latter two cases was not
signiﬁcant.
Independent variables for arterial patency
Estimates of arterial patency after intervention were 90.1% at
1 yr, 75.5% at 2 yr, 68.4% at 3 yr, 61.6% at 5 yr and 49.3% at
10 yr. According to the log rank test with the Kaplan–Meier
method, vascular interventions that were performed at the stable
stage of the disease (P<0.05) and those that were followed
by glucocorticoids and immunosuppressive agents (P<0.05) had
a signiﬁcantly higher patency rate (Fig. 1). A Cox proportional
hazards regression model revealed that the hazard ratio for the
occurrence of restenosis of the former was 0.30, while that of the
latter was 0.41. Demographic data, laboratory ﬁndings (at the time
of intervention), the site of involved arteries, and intervention
modality were not signiﬁcantly associated with the occurrence of
post-interventional vascular restenosis.
Discussion
It is well recognized that restenosis of vascular lesions that have
been revascularized previously by intervention can occur in
patients with TA [25–27]. In this study, 31.7% of revascularized
lesions restenosed after intervention, and the incidence of resteno-
sis was highest within the ﬁrst year and decreased as time passed.
This time-dependent decrement is similar to that observed in
atherosclerosis, but the restenosis rate is much higher than that
seen in cases with atherosclerosis [30–33].
In patients with atherosclerosis, the outcome after surgery seems
to be more favourable than after endovascular procedures. Serruys
et al. [34] evaluated the outcomes of 1205 patients who were






Followed by neither glucocorticoids
nor immunosuppressive
agent (n¼ 24) P
Mean age (yr) 32.0 9.0 32.3 11.1 33.1 9.2 0.551
Mean disease duration (months) 5.7 3.1 4.6 2.4 5.3 2.2 0.641
Disease activity
Active 20 13 5 0.033
Stable 4 2 19 0.040
Laboratory parameters
ESR (mm/h) 45.2 29.0 50.1 20.7 37.3 34.5 0.103
CRP (mg/dl) 2.9 1.5 2.7 1.7 2.0 2.1 0.366
Clinical, laboratory and disease activity-related variables were assessed at the time when the interventions were performed. Data were analysed by
ANOVA.
TABLE 3. Comparison of demographic, clinical, laboratory, intervention-
related and medical treatment-related variables between the interventions





Mean age (yr) 31.9 7.7 32.6 12.0 0.883
Mean disease duration (months) 5.5 2.0 5.0 3.2 0.591
Disease activity
Active 17 21 <0.001
Stable 3 22 0.004
Laboratory parameters
ESR (mm/h) 48.5 30.2 37.4 23.7 0.116
CRP (mg/dl) 2.5 2.0 1.9 1.6 0.219
Modality of intervention
Surgical 4 13 0.297
Endarterectomy 1 2 0.689
Bypass graft 3 11 0.275
Endovascular 16 30 0.297
PTA 4 4 0.214





Glucocorticoid alone 6 9 0.314
No glucocorticoids 12 12 0.024
Aspirin 17 37 0.595
Ticlodipine 13 34 0.187
Clinic and disease activity-related variables were assessed at the time
when the interventions were performed. Data were analysed by
independent t-test or 2 test.
TABLE 2. Incidence of post-interventional vascular restenosis on
follow-up angiography according to the lag time from vascular
interventions
Vascular interventions
Followed by angiography Restenosed
Lag time n n (%)
<1yr 12 6 (50.0%)
1–2 yr 18 8 (44.4%)
2–3 yr 9 3 (33.3%)
3–4 yr 7 1 (14.3%)
4–5 yr 8 1 (12.5%)
5–6 yr 3 0 (0%)
>6yr 6 1 (16.7%)
Total 63 20 (31.7%)




















randomly assigned to undergo stent implantation or bypass
surgery and found that 16.8% of patients in the stent group
underwent a second revascularization, compared with 3.5% from
the surgery group. Stables et al. [35] suggested that the use of
coronary stents has reduced the need for repeat revascularization
compared with balloon angioplasty, though the rate remains
signiﬁcantly higher than in patients managed with bypass surgery.
Similar results favouring surgical revascularization were reported
in patients with TA. Liang et al. [27] described the results of
angiographic follow-ups of 52 vascular interventions in patients
with TA who were in clinical remission and found that the
restenosis rates were as high as 35% after surgery and 57% after
endovascular intervention. Although the short-term beneﬁts of
endovascular interventions in TA, such as the relief of vascular
symptoms, are well deﬁned [19–24], surgery seems to have more
favourable outcomes than endovascular interventions if the
maintenance of vascular patency is considered more important as
a long-term outcome [25–27]. But, in contrast to these previous
ﬁndings, the intervention modality did not affect the vascular
outcome in this study. We found that the more important
determinants of vascular restenosis were active disease at the
time of intervention and the absence of post-interventional
immunosuppressive treatment. This may be because many of
our patients had active vascular inﬂammation at the time they
had undergone vascular intervention. Indeed, the restenosis
rate after interventions that were performed during active disease
was signiﬁcantly higher than that of those performed during
remission in this study, and the outcome of the latter cases was
comparable to that of interventions performed in atherosclerosis
cases [30–36]. Although the exact explanation for the higher
restenosis rate in the active disease group is unclear, active vascular
inﬂammation at the site of intervention might cause restenosis
after intervention, as previously suggested [11, 25–27]. This ﬁnding
thus raises the possibility that the suppression of vascular
inﬂammation with glucocorticoids and/or immunosuppressive
agents may reduce restenosis in patients with TA receiving vascular
interventions.
Ideally, vascular interventions are deferred until disease
activity is controlled by medical treatment because aneurysm
formation, graft dehiscence and graft occlusion are more likely
to occur during active inﬂammation [19, 20]. On the other hand,
Ishikawa et al. [7, 8] suggested that the presence of serious
complications, such as valvular heart disease, cerebrovascular
accidents, congestive heart failure, ischaemic heart disease
and renovascular hypertension, was a signiﬁcant predictor of
mortality in patients with TA, and Kerr et al. [11] reported that
histologically active vasculitis was present in 44% of specimens
obtained from patients with TA who were in clinical remission.
Considering this, delaying intervention until active inﬂammation
is controlled may be harmful in cases involving critical stenosis
and impending organ ischaemia, which should be resolved
immediately. In these cases, prompt intervention is needed,
although this approach may result in a higher rate of restenosis,
to prevent further organ damage, which is associated with a poor
prognosis.
The roles of glucocorticoids and immunosuppressive agents in
TA have been investigated widely. Amelioration of systemic
symptoms was achieved in more than half of glucocorticoid-
treated patients with TA [4, 10]. Meanwhile, immunosuppressive
agents have been reported as effective in controlling disease
activity, even halting the progression of angiographic lesions
[5, 12, 13, 17]. However, reports regarding whether glucocorticoids
arrest angiographic progression are conﬂicting, and previous
studies have shown that glucocorticoids alone in active TA are
successful in arresting disease progression in fewer than 50% of
patients, necessitating the use of additional immunosuppres-
sive agents [11, 14, 37, 38]. In this study, the administration of
glucocorticoids and immunosuppressive agents was performed in a
manner similar to standard protocols used in previous studies
[11–16], and we found that glucocorticoids used in conjunction
with immunosuppressive agents signiﬁcantly reduced the risk
of vascular restenosis. Although interventions followed by gluco-
corticoids alone showed a lower restenosis rate than those not
followed by medical treatment, glucocorticoids alone did
not reduce the rate of restenosis signiﬁcantly in this study. This
result, along with those from previous studies, suggests that
glucocorticoids alone may be insufﬁcient to prevent vascular
restenosis; thus, the addition of immunosuppressive agents to
glucocorticoid treatment is needed to maintain arterial patency
after intervention.
This study was performed in a retrospective manner and has
some potential limitations: (i) heterogeneous treatment modalities
and the treatment durations present a risk of signiﬁcant bias
when assessing the effects of the medical treatments on vascular
outcome; and (ii) although the addition of immunosuppressive
agents to glucocorticoids was allocated in a random manner, the
initiation of glucocorticoids was allocated based on the clinical and
laboratory ﬁndings, which also can cause a bias inﬂuencing the
differences in vascular outcomes. In order to clarify these issues,
prospective controlled studies will be needed to better identify the
FIG. 1. Comparison of patency rates of revascularized lesion
after interventions. (A) Patency rate of revascularized lesions was
higher after interventions performed at the stable stage
(continuous line) than after interventions at the active stage
(dashed line) (P¼ 0.005). (B) Patency of revascularized lesion
was well maintained when glucocorticoid with immunosuppres-
sive agent had been added after intervention (continuous line)
compared with interventions followed by glucocorticoid alone
(dotted line) (P¼ 0.015).




















effects of the medical treatment and disease activity on vascular
outcome.
In practice, it is important to revascularize the stenosis with
surgical or endovascular interventions to prevent further organ
damage in patients with TA. However, the maintenance of arterial
patency is also important, as frequent restenosis of vascular lesions
may lead to serious complications and a decrease in quality of
life. In cases of mild and non-urgent stenosis, controlling vascular
inﬂammation with medical treatment prior to vascular inter-
vention seems to be beneﬁcial. However, prompt revascularization
procedures are needed in cases with severe stenosis or impending
organ ischaemia, with more favourable outcomes expected
if they are followed by post-interventional immunosuppressive
treatment.
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